On July 14, GlaxoSmithKline (GSK) announced its plans to invest £60 million ($97 million) in AIDS treatment in Africa over the next ten years. The company’s plans focus primarily on the care and treatment of children with HIV and AIDS as well as improved access to antiretroviral drugs.

Andrew Witty, the Chief Executive Officer of GSK, outlined several programs aimed to help those living with HIV and AIDS in Sub-Saharan Africa. According to the World Health Organization, more than three-quarters of all AIDS related deaths occurred in this region in…